# A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

> **NCT05196035** · PHASE3 · RECRUITING · sponsor: **Bayer** · enrollment: 219 (estimated)

## Conditions studied

- Chronic Kidney Disease
- Proteinuria

## Interventions

- **DRUG:** Finerenone (Kerendia, BAY94-8862)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05196035
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-28
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 219 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05196035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05196035, "A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05196035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*